TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action

Benzinga Logo Benzinga • •By Business Wire
Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action

MoonLake Immunotherapeutics experienced a significant stock drop after announcing disappointing Phase 3 results for its drug candidate sonelokimab, which failed to match competitor's drug efficacy, leading to a potential securities fraud class action lawsuit.

Insights
MSFT   neutral

Mentioned as a participant providing insights on AI's role in insurance landscape


MLTX   negative

Stock dropped 89.9% after revealing ineffective drug trial results, potential misrepresentation of drug capabilities, and facing a class action lawsuit